CBT-3112

N/A

Report date: 2024/11/18 13:25:57

Base Information

Drug NameCBT-3112
Drug Alias NameCBT3112
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionSerine/threonine-protein kinase DCLK1 modulators
TargetsSerine/threonine-protein kinase DCLK1
Therapy Area/IndicationsPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCoare Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesCoare Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A